Form 4: Pliant Therapeutics CEO Executes Stock Option Repricing

Pliant Therapeutics CEO Bernard Coulie has repriced multiple tranches of stock options to $1.33 per share following board approval.

Summary

• Pliant Therapeutics (PLRX) implemented a company-wide stock option repricing program effective April 17, 2026.
• CEO Bernard Coulie participated in the repricing, which adjusted the exercise prices of seven distinct option grants to $1.33 per share.
• The original exercise prices for these options ranged from $2.08 to $34.65.
• The repricing applies to all stock options granted on or before March 1, 2025, to current employees.
• A retention period is in place where options revert to original exercise prices if exercised within 18 months or if the employee resigns without 'good reason'.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative event; while it indicates past share price weakness, it is a standard retention tool for executive and employee compensation.

Positives

• Aligns management incentives with current market valuation by adjusting underwater options.
• Retention mechanism ensures that the repricing benefit is tied to continued service and performance.

Negatives

• Repricing underwater options often signals that previous equity-based compensation targets were not met due to share price decline.
• Potential for shareholder dilution concerns regarding the value of repriced equity.

Risks

• The retention period requires the CEO to remain with the company for up to 18 months to maintain the lower exercise price.
• If the company undergoes a corporate transaction or sale event, the retention period may be triggered, potentially impacting the value of these options.

Future Outlook

The company has implemented an 18-month retention period for the repriced options, signaling a focus on executive stability and long-term alignment with the current share price.

Management Comments

• The board approved the repricing to ensure that equity incentives remain effective for current employees.
• Repriced options will revert to original exercise prices if exercised during the 18-month retention period or if the employee leaves under certain conditions.

Industry Context

StockSavvy.ai notes that option repricing is a common, albeit sensitive, practice in the biotechnology sector when share prices experience significant volatility or decline, aimed at preventing the loss of key talent whose existing equity grants have become 'underwater'.

Comparison to Industry Standards

• Repricing programs are frequently utilized by clinical-stage biotech firms to maintain employee retention during prolonged development cycles.
• The inclusion of a strict 18-month retention period is a standard governance practice to mitigate shareholder criticism regarding 'windfall' gains.

Corporate Governance

Stakeholder Impact

• Shareholders may view the repricing as a dilution of the original strike price value.
• Employees and executives benefit from the increased likelihood of their options becoming 'in-the-money'.

Next Steps

• Monitoring of the 18-month retention period for the CEO's repriced options.
• Continued observation of Pliant Therapeutics' clinical development milestones.

Key Dates

Keywords

Pliant Therapeutics, PLRX, Stock Option Repricing, Executive Compensation, Insider Transaction, Biotech